Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total transaction of $110,400.00. Following the sale, the director directly owned 6,169,863 shares in the company, valued at $22,705,095.84. This represents a 0.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, May 5th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $105,600.00.
• On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.10, for a total transaction of $93,000.00.

Recursion Pharmaceuticals Stock Down 12.6%

Shares of RXRX opened at $3.32 on Friday. The stock has a market capitalization of $1.76 billion, a PE ratio of -2.77 and a beta of 1.04. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.77 and a 1 year high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. The company’s 50-day simple moving average is $3.30 and its 200-day simple moving average is $3.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. The business had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The business’s quarterly revenue was down 56.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) earnings per share. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Morgan Stanley raised their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a report on Thursday, May 14th. JPMorgan Chase & Co. reduced their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Finally, Bank of America reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $8.10.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in RXRX. Brighton Jones LLC increased its stake in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after purchasing an additional 6,699 shares during the last quarter. Royal Bank of Canada increased its stake in Recursion Pharmaceuticals by 627.6% in the first quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC purchased a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Recursion Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after purchasing an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth purchased a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $77,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion’s recent business updates highlighted positive early clinical data and further progress in its AI drug-discovery pipeline, reinforcing investor optimism about the company’s long-term platform potential. Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
• Positive Sentiment: The company reported a smaller-than-expected quarterly EPS loss and better-than-expected revenue in its latest earnings release, which helped support the recent rebound in the stock. Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Recent commentary also focused on Recursion’s valuation and the market’s patience with its AI-biotech story, suggesting investors are weighing pipeline upside against a still-uncertain commercialization timeline. Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
• Negative Sentiment: CEO Najat Khan sold shares in a pre-arranged trading plan, and Director Namandje Bumpus also sold shares, adding a mild overhang as investors may view insider selling cautiously even though the transactions were planned in advance. SEC filing for CEO Najat Khan sale SEC filing for Director Namandje Bumpus sale

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.